NICE recommends epcoritamab for relapsed or refractory follicular lymphoma

AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL

FDA accepts Genentech application for giredestrant combination in ESR1-mutated advanced breast cancer

FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL

Moleculin exercises warrants for USD8.3m gross proceeds

Eupraxia Pharmaceuticals prices USD55m public offering

Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research

EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer

Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons

AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study

Cedar Health Research opens new embedded research site within Texas Native Health

Hansa's imlifidase Biologics License Application accepted by FDA

Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria

Merck and Mayo Clinic launch AI-driven drug discovery collaboration

Palisade Bio makes Clinical Advisory Board appointment